Lucid Diagnostics reports real-world data from 12,000 esophageal tests
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
December 9, 2025 8:01 AM ESTReport includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device
Real-world data confirm excellent technical performance, very rapid cell-collection times, and appropriate physician use, consistent with previously published studies
NEW YORK, Dec. 9, 2025 /PRNewswire/ --... More
